ISIS

Isis Pharmaceuticals, Inc. Press Releases

$41.24
*  
1.37
3.44%
Get ISIS Alerts
*Delayed - data as of Oct. 20, 2014 14:32 ET  -  Find a broker to begin trading ISIS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    ISIS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy
10/10/2014 4:30:00 AM - PR Newswire
▲10.86 % Price Change since this news event. The Volume Ratio is 2.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx
10/9/2014 7:00:00 AM - PR Newswire
▲5.47 % Price Change since this news event. The Volume Ratio is 1.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress
10/2/2014 7:00:00 AM - PR Newswire


Isis Pharmaceuticals Earns $1.5 Million From GSK for the Advancement of ISIS-GSK4 Rx
10/1/2014 7:00:00 AM - PR Newswire


Isis Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable
9/24/2014 7:00:00 AM - PR Newswire


Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin
9/17/2014 7:26:00 AM - PR Newswire


Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
9/3/2014 7:00:00 AM - PR Newswire


ATL1103 Phase II Trial - Successful Efficacy Results
9/2/2014 7:19:00 PM - PR Newswire


Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014
9/2/2014 7:00:00 AM - PR Newswire


Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
8/28/2014 7:00:00 AM - PR Newswire


Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
8/15/2014 7:00:00 AM - PR Newswire


Isis Reports Financial Results and Highlights for Second Quarter 2014
8/4/2014 8:30:00 AM - PR Newswire


Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
8/1/2014 7:00:00 AM - PR Newswire


Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
7/28/2014 7:00:00 AM - PR Newswire